Search In this Thesis
   Search In this Thesis  
العنوان
New Trends in Analysis of Peptidomimetic and Non-Peptidomimetic Inhibitors in Pharmaceutical Dosage Forms and Biological Fluids /
المؤلف
Daoud, Amira Mohamed Mahmoud Ali.
هيئة الاعداد
باحث / Amira Mohamed Mahmoud Ali Daoud
مشرف / Mohamed Mohamed Salem Rizk
مشرف / Emad Mohamed Hussien
مشرف / Rasha Mohamed Tharwat Eleryan
تاريخ النشر
2021.
عدد الصفحات
I-XXV,171 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الصيدلة ، علم السموم والصيدلانيات
الناشر
تاريخ الإجازة
1/1/2021
مكان الإجازة
جامعة حلوان - كلية الصيدلة - Pharmaceutical Analytical Chemistry
الفهرس
Only 14 pages are availabe for public view

from 235

from 235

Abstract

Summary
The thesis is concerned with developing simple, economic, accurate, precise, sensitive and quantitative methods for the analysis of peptidomimetic and non-peptidomimetic inhibitors namely Oxymetazoline hydrochloride (OXM), Vilazodone hydrochloride (VLZ), Secnidazole (SCZ) and Naratriptan hydrochloride (NTP) in their drug substance, pharmaceutical dosage forms and/or biological fluids.
All parameters affecting the proposed methods were investigated and optimized regarding accuracy, sensitivity and selectivity. Validation procedures according to ICH guidelines were performed and the results were statistically analyzed and compared with reference methods.
The thesis consists of five parts in addition to references and summary in Arabic.
Part I: Introduction
This part includes general introduction of peptidomimetics and non peptidomimetics inhibitors, their classifications, modifications and advantages, also an introduction on analytical techniques applied.
Part II: Oxymetazoline hydrochloride
This part includes:
Section A: General introduction and literature review 
The section introduces a general introduction about OXM, the physicochemical properties, pharmacological action and literature review involving some reported methods for the determination of OXM in drug substance and dosage form.
Section B: All-solid-state polymeric screen printed and carbon paste ion selective electrodes for determination of OXM in pharmaceutical dosage form
This section described for the first time a disposable home-made screen printed electrode (SPE) for determination of OXM in pharmaceutical dosage form and drug substance. ISEs with optimal potentiometric response were achieved by careful selection of the ion exchanger and plasticizer. A SPE utilizing OXM-TPB as an ion exchanger and DBP as a plasticizer exhibited a Nernstian slope of 59.5±0.5 mV/decade (n=3) over the concentration range from 1x10-5 to 1x10-2 M OXM with a detection limit of 5.01x10-6 M. The electrode is useful over a wide pH range from 4 to 9. The electrode showed a high selectivity for OXM against several common interfering ions. The potential interference from benzalkonium chloride was easily eliminated by treatment the sample with KI. Comparable potentiometric characteristics were obtained with a CPE comprising same ion exchanger and plasticizer. The electrodes were successfully used for the assay of OXM in the drug substance and in the dosage form in presence of benzalkonium chloride with high accuracy and precision. The proposed method is simple, accurate and precise.
Section C: Voltammetric analysis of OXM at zeolite -modified carbon paste electrode in micellar medium
A Simple, sensitive, accurate and inexpensive differential pulse (DPV) and square wave (SWV) voltammetric methods utilizing zeolite modified carbon paste electrode (ZMCPE) were developed for the determination of OXM in dosage form. 
Various experimental parameters were optimized using cyclic voltammetry (CV). Controlled adsorption of OXM onto the electrode surface and working in a micellar medium allowed the determination of OXM at low concentrations. Calibration curves were linear over the concentration ranges 9.83x10-8 - 3.60x10-6 M and 9.83x10-6 - 9.03x10-5 M for DPV and SWV, respectively. Validation results showed satisfactory accuracy with high %recovery and good precision with low %RSD (0.9%). The method was applied for the determination of OXM in pharmaceutical formulation with an average recovery of 101.18 % (%RSD=0.41, n=9).